Chaudhry Salman, Fields Ryan C, Grierson Patrick M, Lim Kian-Huat
Comprehensive Cancer Center, Division of Oncology, Department of Internal Medicine, Barnes-Jewish Hospital and The Alvin J. Siteman, Washington University School of Medicine, St. Louis, MO 63110, USA.
Comprehensive Cancer Center, Section of Surgical Oncology, Department of Surgery, Barnes-Jewish Hospital and The Alvin J. Siteman, Washington University School of Medicine, St. Louis, MO 63110, USA.
Cancers (Basel). 2021 Mar 13;13(6):1283. doi: 10.3390/cancers13061283.
Colorectal cancer (CRC) is the third most prevalent malignancy and the second most common cause of death in the US. Liver is the most common site of colorectal metastases. About 13% of patients with colorectal cancer have liver metastasis on initial presentation and 50% develop them during the disease course. Although systemic chemotherapy and immunotherapy are the mainstay treatment for patients with metastatic disease, for selected patients with predominant liver metastasis, liver-directed approaches may provide prolonged disease control when combined with systemic treatments. Hepatic artery infusion pump (HAIP) chemotherapy is an approach which allows direct infusion of chemotherapeutic into the liver and is especially useful in the setting of multifocal liver metastases. When combined with systemic chemotherapy, HAIP improves the response rate, provides more durable disease control, and in some patients leads to successful resection. To ensure safety, use of HAIP requires multidisciplinary collaboration between interventional radiologists, medical oncologists, hepatobiliary surgeons and treatment nurses. Here, we review the benefits and potential risks with this approach and provide our single institution experience on two CRC patients successfully treated with HAIP in combination with systemic chemotherapy. We provide our recommendations in adopting this technique in the current era for patient with colorectal liver metastases.
结直肠癌(CRC)是美国第三大常见恶性肿瘤,也是第二大常见死因。肝脏是结直肠癌转移最常见的部位。约13%的结直肠癌患者初诊时即有肝转移,50%的患者在疾病过程中会出现肝转移。尽管全身化疗和免疫治疗是转移性疾病患者的主要治疗方法,但对于部分以肝转移为主的特定患者,肝靶向治疗方法与全身治疗联合使用时,可能会延长疾病控制时间。肝动脉灌注泵(HAIP)化疗是一种可将化疗药物直接注入肝脏的方法,在多灶性肝转移的情况下尤其有用。与全身化疗联合使用时,HAIP可提高缓解率,提供更持久的疾病控制,并且在一些患者中可实现成功切除。为确保安全,使用HAIP需要介入放射科医生、医学肿瘤学家、肝胆外科医生和治疗护士之间的多学科协作。在此,我们回顾了这种方法的益处和潜在风险,并介绍了我们单机构对两名成功接受HAIP联合全身化疗治疗的结直肠癌患者的经验。我们给出了在当前时代对结直肠癌肝转移患者采用这种技术的建议。